EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms

Swastika Maity, Krishnaprasad Baby, Bharath Harohalli Byregowda iD, Megh Pravin Vithalkar iD, Usha Y Nayak iD, K Sreedhara Ranganath Pai iD, Yogendra Nayak iD

F1000Research · 2025

DOI: 10.12688/f1000research.157465.2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift F1000Research, 2025. Verfasst von Swastika Maity und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Acenocoumarol, Signal Transduction. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research, Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-small-cell lung cancer (NSCLC) is a highly morbid disease. Chemotherapy for NSCLC lacks specificity and efficacy mainly because of drug resistance. The current study aimed to explore computational tools to target allosteric epidermal growth factor receptor (EGFR) sites and screen for the top molecules in vitro and in vivo xenograft models.

Methods

Molecular docking, virtual screening, and molecular dynamic studies revealed that acenocoumarol and silodosin are the top two allosteric EGFR inhibitors. They were further tested for cytotoxicity, apoptosis, cell cycle, and gene expression by qPCR, western blotting, A549 cell xenograft anti-proliferative activity, and tumor regression efficacy analysis.

Results

Acenocoumarol and silodosin exhibited cytotoxicity in A549 and IMR-90 cells at concentrations below 50 and 80 μM, respectively. Acenocoumarol and silodosin induced S-phase and G2/M-phase arrest in A549 cells in the cell cycle analysis. Both drugs showed early apoptosis at their IC 50 doses (acenocoumarol 50 μM and silodosin 25 μM). KRAS (Kirsten rat sarcoma viral oncogene homolog) and ERK2 (extracellular signal-regulated kinase 2) gene regulation in A549 cells was confirmed using qPCR. KRAS and ERK2 activities were quantified by western blot analysis. In the xenograft study, tumor size, body weight, and organ weight were significantly attenuated by the test drugs compared with the standard cisplatin. Immunoblotting and western blot results of the A549-xenograft tissue indicated downregulation of KRAS and ERK2. Furthermore, the test drugs have upregulated caspase-3 gene expression.

Conclusion

The drugs acenocoumarol and silodosin downregulate KRAS and ERK2 in both A549 cell lines and Xenograft model. KRAS and ERK2 are components of EGFR-associated signaling pathways. Hence, acenocoumarol and silodosin can be further explored as repurposed candidates in future preclinical and clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAcenocoumarolSignal TransductionIndolesAntineoplastic AgentsHumansErbB ReceptorsAnimalsMiceXenograft Model Antitumor AssaysMolecular Docking SimulationCell Line, TumorApoptosisMice, NudeA549 CellsCell Proliferation

Stichwörter der Autor:innen

AcenocoumarolAllosteric EGFR inhibitorDrug repurposingNSCLCSilodosin

Substanzen

ErbB ReceptorsEGFR protein, humanAcenocoumarolIndolesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
  • Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.

ORCID-Profile: Bharath Harohalli Byregowda, Megh Pravin Vithalkar, Usha Y Nayak, K Sreedhara Ranganath Pai, Yogendra Nayak

Förderung

  • Indian Council of Medical Research
  • Science and Engineering Research Board

Zitieren

APA

Maity, S., Baby, K., Byregowda, B. H., Vithalkar, M. P., Nayak, U. Y., Pai, K. S. R., & Nayak, Y. (2025). Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms. F1000Research. https://doi.org/10.12688/f1000research.157465.2

Vancouver

Maity S, Baby K, Byregowda BH, Vithalkar MP, Nayak UY, Pai KSR, et al. Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms. F1000Research. 2025. doi:10.12688/f1000research.157465.2

BibTeX
@article{Maity2025,
  author = {Maity, Swastika and Baby, Krishnaprasad and Byregowda, Bharath Harohalli and Vithalkar, Megh Pravin and Nayak, Usha Y and Pai, K Sreedhara Ranganath and Nayak, Yogendra},
  title = {Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms},
  journal = {F1000Research},
  year = {2025},
  doi = {10.12688/f1000research.157465.2}
}
Kostenlos starten →